435 related articles for article (PubMed ID: 33065367)
21. A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
Quan MV; Frankel SK; Maleki-Fischbach M; Tan LD
BMC Pulm Med; 2018 Nov; 18(1):181. PubMed ID: 30497438
[TBL] [Abstract][Full Text] [Related]
22. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
[TBL] [Abstract][Full Text] [Related]
23. A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.
Koike H; Nishi R; Yagi S; Furukawa S; Fukami Y; Iijima M; Katsuno M
Adv Ther; 2023 Jan; 40(1):25-40. PubMed ID: 36152266
[TBL] [Abstract][Full Text] [Related]
24. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis.
Mümmler C; Mertsch P; Barnikel M; Haubner F; Schönermarck U; Grabmaier U; Schulze-Koops H; Behr J; Kneidinger N; Milger K
J Asthma Allergy; 2024; 17():557-572. PubMed ID: 38860030
[TBL] [Abstract][Full Text] [Related]
25. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
26. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
27. Advances in the pharmacotherapeutic management of eosinophilic granulomatosis with polyangiitis.
Pagnoux C; Berti A
Expert Opin Pharmacother; 2023; 24(11):1269-1281. PubMed ID: 37204027
[TBL] [Abstract][Full Text] [Related]
28. Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy.
Matsuno O
Int Arch Allergy Immunol; 2024; 185(2):116-123. PubMed ID: 37906985
[TBL] [Abstract][Full Text] [Related]
29. Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group.
Caminati M; Fassio A; Alberici F; Baldini C; Bello F; Cameli P; Conticini E; Cottin V; Crimi C; Dagna L; Delvino P; Deroux A; Duran E; Espigol-Frigole G; Karadag O; Maule M; Moiseev S; Monti S; Moroni L; Padoan R; Pugnet G; Taille C; Toniati P; Vaglio A; Emmi G
Allergy; 2024 Feb; 79(2):516-519. PubMed ID: 37904674
[No Abstract] [Full Text] [Related]
30. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis.
Ueno M; Miyagawa I; Nakano K; Iwata S; Hanami K; Fukuyo S; Kubo S; Miyazaki Y; Kawabe A; Yoshinari H; Nakayamada S; Tanaka Y
Arthritis Res Ther; 2021 Mar; 23(1):86. PubMed ID: 33726827
[TBL] [Abstract][Full Text] [Related]
32. Anti-IL5 Monoclonal Antibodies Reduce Asthma Exacerbations and Corticosteroids Dose in Three Eosinophilic Granulomatosis with Polyangiitis Case Reports.
Skouvaklidou E; Kipourou M; Zisopoulos D; Vounotrypidis P; Katsoulis K
Mediterr J Rheumatol; 2023 Jun; 34(2):238-244. PubMed ID: 37654647
[TBL] [Abstract][Full Text] [Related]
33. Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab.
Ricciardi L; Soler DG; Bennici A; Brunetto S; Pioggia G; Gangemi S
Front Pharmacol; 2022; 13():858344. PubMed ID: 35462932
[No Abstract] [Full Text] [Related]
34. Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions.
Ushio Y; Wakiya R; Kato M; Kameda T; Nakashima S; Shimada H; Mansour MMF; Sugihara K; Miyashita T; Kadowaki N; Dobashi H
Mod Rheumatol Case Rep; 2021 Jul; 5(2):327-332. PubMed ID: 33533698
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States.
Silver J; Deb A; Packnett E; McMorrow D; Morrow C; Bogart M
J Clin Rheumatol; 2023 Dec; 29(8):381-387. PubMed ID: 37779234
[TBL] [Abstract][Full Text] [Related]
36. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis (EGPA) in Japan: 48-week interim analysis of the MARS study.
Ishii T; Kunishige H; Kobayashi T; Hayashi E; Komatsubara M; Ishii T; Alfonso-Cristancho R; Tamaoki J; Howarth P
Mod Rheumatol; 2023 Dec; ():. PubMed ID: 38100679
[TBL] [Abstract][Full Text] [Related]
37. Biologics for eosinophilic granulomatosis with polyangiitis.
Caminati M; Maule M; Bello F; Emmi G
Curr Opin Allergy Clin Immunol; 2023 Feb; 23(1):36-43. PubMed ID: 36413432
[TBL] [Abstract][Full Text] [Related]
38. [Anti-IL-5 in severe asthma associated with eosinophilic granulomatosis with polyangiitis. Real-life study].
Akdime F; Habib S; Regard L; Terrier B; Cohen P; Mouthon L; Guillevin L; Burgel PR; Honore I; Puéchal X; Roche N
Rev Mal Respir; 2023; 40(9-10):732-742. PubMed ID: 37923651
[TBL] [Abstract][Full Text] [Related]
39. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
[TBL] [Abstract][Full Text] [Related]
40. Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis.
Tsurikisawa N; Oshikata C; Watanabe M; Tsuburai T; Kaneko T; Saito H
Clin Exp Allergy; 2018 Oct; 48(10):1305-1316. PubMed ID: 29908086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
